In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex

In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex Publisher

Khoshandam M¹ ; Soheili ZS¹ ; Hosseinkhani S² ; Samiee S³ ; Latifinavid H^{1, 6, 7} ; Ahmadieh H⁴ ; Soltaninejad H⁵ ; Jahangiri B¹

Show Affiliations

1. Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
2. Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
3. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
4. Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5. Department of stem cells technology and Tissue Regeneration, Faculty of Interdisciplinary Science and Technologies, Tarbiat Modares University, Tehran, Iran
6. School of Biological Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran
7. Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Translational Oncology Published:2025

Abstract

The inhibition of angiogenesis is a crucial therapeutic strategy in cancer treatment, as it limits tumor growth and metastasis. In this study, we investigate the anti-angiogenic potential of a novel htsFLT01/MiRGD nanocomplex, designed to target key angiogenesis markers in cancer. This nanocomplex integrates the anti-angiogenic fusion protein htsFLT01 with the MiRGD peptide to enhance its efficacy. Our findings demonstrate that htsFLT01/MiRGD effectively suppresses angiogenesis both in vitro and in vivo, particularly in breast cancer models. Histological and molecular analyses reveal a significant reduction in blood vessel formation, accompanied by structural changes in tumor tissue. Furthermore, the expression levels of key angiogenesis-related genes, including VEGF, VEGFR, and CD31, are markedly downregulated, highlighting the therapeutic potential of this nanocomplex. Beyond its anti-angiogenic effects, the treatment also induces apoptosis and inhibits tumor cell proliferation, reinforcing its role as a promising targeted therapy for angiogenesis-dependent malignancies. These results underscore the potential of htsFLT01/MiRGD in cancer treatment and pave the way for future clinical applications in anti-angiogenic therapies. © 2025

2. Recent Advances in Gene Therapy-Based Cancer Monotherapy and Synergistic Bimodal Therapy Using Upconversion Nanoparticles: Structural and Biological Aspects, Biomedicine and Pharmacotherapy (2022)

3. Repurposing the Anti-Parasitic Agent Pentamidine for Cancer Therapy; a Novel Approach With Promising Anti-Tumor Properties, Journal of Translational Medicine (2025)

Experts (# of related papers)

View all Related Experts

Ali Abbasi (1)

Vahid Haghpanah (1)

Style	Citing Format
MLA	Khoshandam M, et al.. "In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex." Translational Oncology, vol. 56, no. , 2025, pp. -.
APA	Khoshandam M, Soheili ZS, Hosseinkhani S, Samiee S, Latifinavid H, Ahmadieh H, Soltaninejad H, Jahangiri B (2025). In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex. Translational Oncology, 56(), -.
Chicago	Khoshandam M, Soheili ZS, Hosseinkhani S, Samiee S, Latifinavid H, Ahmadieh H, Soltaninejad H, Jahangiri B. "In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex." Translational Oncology 56, no. (2025): -.
Harvard	Khoshandam M et al. (2025) 'In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex', Translational Oncology, 56(), pp. -.
Vancouver	Khoshandam M, Soheili ZS, Hosseinkhani S, Samiee S, Latifinavid H, Ahmadieh H, et al.. In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex. Translational Oncology. 2025;56():-.
BibTex	@article{ author = {Khoshandam M and Soheili ZS and Hosseinkhani S and Samiee S and Latifinavid H and Ahmadieh H and Soltaninejad H and Jahangiri B}, title = {In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex}, journal = {Translational Oncology}, volume = {56}, number = {}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Khoshandam M AU - Soheili ZS AU - Hosseinkhani S AU - Samiee S AU - Latifinavid H AU - Ahmadieh H AU - Soltaninejad H AU - Jahangiri B TI - In Vivo Inhibition of Angiogenesis by Htsflt01/Mirgd Nano Complex JO - Translational Oncology VL - 56 IS - SP - EP - PY - 2025 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract